Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Motion Sickness Treatment Market, by Drug Class
1.4.2 North America Motion Sickness Treatment Market, by Route of Administration
1.4.3 North America Motion Sickness Treatment Market, by Distribution Channel
1.4.4 North America Motion Sickness Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Motion Sickness Treatment Market by Drug Class
3.1 North America Antihistamines Market by Country
3.2 North America Anticholinergics Market by Country
3.3 North America Others Market by Country
Chapter 4. North America Motion Sickness Treatment Market by Route of Administration
4.1 North America Oral Market by Country
4.2 North America Others Market by Country
Chapter 5. North America Motion Sickness Treatment Market by Distribution Channel
5.1 North America Drug Store & Retail Pharmacies Market by Country
5.2 North America Hospital Pharmacies Market by Country
5.3 North America Online Pharmacies Market by Country
Chapter 6. North America Motion Sickness Treatment Market by Country
6.1 US Motion Sickness Treatment Market
6.1.1 US Motion Sickness Treatment Market by Drug Class
6.1.2 US Motion Sickness Treatment Market by Route of Administration
6.1.3 US Motion Sickness Treatment Market by Distribution Channel
6.2 Canada Motion Sickness Treatment Market
6.2.1 Canada Motion Sickness Treatment Market by Drug Class
6.2.2 Canada Motion Sickness Treatment Market by Route of Administration
6.2.3 Canada Motion Sickness Treatment Market by Distribution Channel
6.3 Mexico Motion Sickness Treatment Market
6.3.1 Mexico Motion Sickness Treatment Market by Drug Class
6.3.2 Mexico Motion Sickness Treatment Market by Route of Administration
6.3.3 Mexico Motion Sickness Treatment Market by Distribution Channel
6.4 Rest of North America Motion Sickness Treatment Market
6.4.1 Rest of North America Motion Sickness Treatment Market by Drug Class
6.4.2 Rest of North America Motion Sickness Treatment Market by Route of Administration
6.4.3 Rest of North America Motion Sickness Treatment Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Viatris, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental Analysis
7.1.4 Research & Development Expense
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Amneal Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental Analysis
7.3.4 Research & Development Expenses
7.4 Baxter International, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental Analysis
7.4.4 Research & Development Expense
7.5 Novartis AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Abbott Laboratories
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 SWOT Analysis
7.7 Sun Pharmaceutical Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Zydus Lifesciences Ltd.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Trials and Approvals:
7.9 Prestige Consumer Healthcare, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.10. WellSpring Pharmaceutical Corporation (Avista Capital Partners)
7.10.1 Company Overview
Unique Offerings 